STOCK TITAN
  1. Home
  2. Sec-filings
  3. BSX
  4. [Form 4] BOSTON SCIENTIFIC CORP Insider Trading Activity

[Form 4] BOSTON SCIENTIFIC CORP Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Morano Susan E reported acquisition or exercise transactions in this Form 4 filing.

Boston Scientific director Susan E. Morano reported two equity compensation grants of common stock. She received 1,281 shares as an annual equity award of restricted stock and 3,800 shares of restricted stock granted in lieu of 50% of her yearly cash compensation. Both grants vest in full at the next annual meeting of stockholders.

The annual equity award reflects a value of $215,000 based on the closing share price on the grant date. The stock granted in place of cash has an approximate value of $72,500, tied to the non-employee director cash retainer and committee chair retainer. These are compensation-related awards, not open‑market share purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Morano Susan E
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 3,800 $0.00 $0.00
Grant/Award Common Stock 1,281 $0.00 $0.00
Holdings After Transaction: Common Stock — 11,744 shares (Direct)
Footnotes (2)
  1. F1. Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.
  2. F2. Grant of restricted stock in lieu of 50% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of approximately $72,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000 and committee chair retainer having a value of $20,000) divided by the closing price of the common stock on the date of grant.
Annual equity award shares 1,281 shares Restricted stock annual equity award to director
Stock in lieu of cash shares 3,800 shares Restricted stock granted instead of 50% yearly cash compensation
Annual equity award value $215,000 Value of restricted stock annual equity award, based on closing price
Stock in lieu of cash value approximately $72,500 Value of restricted stock replacing 50% yearly cash compensation
Cash retainer reference $125,000 Non-employee director compensation program cash retainer amount
Committee chair retainer $20,000 Committee chair retainer amount used in stock-in-lieu calculation
restricted stock financial
"Annual equity award in the form of restricted stock vesting in full upon the next annual meeting"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
annual equity award financial
"Annual equity award in the form of restricted stock vesting in full upon the next annual meeting"
non-employee director compensation program financial
"representing 50% of the amount of the non-employee director compensation program's cash retainer"
cash retainer financial
"cash retainer having a value of $125,000 and committee chair retainer having a value of $20,000"
committee chair retainer financial
"cash retainer having a value of $125,000 and committee chair retainer having a value of $20,000"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did Boston Scientific (BSX) director Susan E. Morano report in this Form 4?
Susan E. Morano reported receiving two restricted stock awards of Boston Scientific common stock as compensation. These equity grants replace or supplement cash fees and are not open-market trades, so they primarily reflect how the company structures director pay.

How many Boston Scientific (BSX) shares were granted to Susan E. Morano?
Susan E. Morano received 1,281 shares of restricted stock as an annual equity award and 3,800 restricted shares granted in lieu of part of her yearly cash compensation. Both awards are classified as acquisitions under code A on the Form 4.

What is the dollar value of Susan E. Morano’s Boston Scientific equity awards?
The annual equity award reflects a value of $215,000, based on the closing stock price on the grant date. The restricted stock granted instead of cash compensation has an approximate value of $72,500, tied to Boston Scientific’s non-employee director and committee chair retainers.

When do Susan E. Morano’s Boston Scientific restricted stock awards vest?
Both restricted stock awards vest in full at Boston Scientific’s next annual meeting of stockholders. Until vesting, the shares are subject to restrictions typical for director equity compensation, after which they generally become fully owned by the director.

Are Susan E. Morano’s Boston Scientific (BSX) transactions open-market buys or sells?
No, these are not open-market buys or sells. The Form 4 shows code A transactions, meaning the shares were granted as compensation awards of restricted stock, including an annual equity award and stock issued instead of part of her cash fees.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Morano Susan E
(Last)(First)(Middle)
300 BOSTON SCIENTIFIC WAY
(Street)
MARLBOROUGH MASSACHUSETTS 01752-1234
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/07/2026A(1)3,800A$0.000010,463D
Common Stock05/07/2026A(2)1,281A$0.000011,744D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.
2. Grant of restricted stock in lieu of 50% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of approximately $72,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000 and committee chair retainer having a value of $20,000) divided by the closing price of the common stock on the date of grant.
/s/ Susan Thompson, Attorney-in-Fact05/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR